Health & Fitness
Thu, November 8, 2012Wed, November 7, 2012Tue, November 6, 2012Mon, November 5, 2012Sat, November 3, 2012Fri, November 2, 2012Thu, November 1, 2012Wed, October 31, 2012Tue, October 30, 2012Mon, October 29, 2012Sun, October 28, 2012Fri, October 26, 2012Thu, October 25, 2012Wed, October 24, 2012Tue, October 23, 2012Mon, October 22, 2012Sun, October 21, 2012Sat, October 20, 2012Fri, October 19, 2012Thu, October 18, 2012Wed, October 17, 2012Tue, October 16, 2012Mon, October 15, 2012Analyst Opinion on Eli Lilly &;; Co. and Pfizer Inc. -- Drug Manufacturers Countering Patent Expirations with New Pro
Published in Health and Fitness on Monday, October 29th 2012 at 7:31 GMT by Market Wire
October 29, 2012 10:17 ET
Analyst Opinion on Eli Lilly & Co. and Pfizer Inc. -- Drug Manufacturers Countering Patent Expirations with New Products
LONDON--(Marketwire - Oct 29, 2012) - The drug manufacturers - major industry, which includes players such as Eli Lilly & Co. and Pfizer Inc., has been facing challenging times of late. Patent expirations continue to put dents in revenue and earnings and with more expiration upcoming, it is essential for companies to bring new products to the market.
[ www.WallStreetActive.com ] is unswerving when it comes teaching the new and pro traders on how to take the helm in a market environment that has been seeing waves upon waves of changes and reap the rewards of participating in various sectors. We invite serious traders to join our financial community so that they can benefit from our free analytical coverage on Eli Lilly & Co. (
[ http://www.wallstreetactive.com/register.php ]
Pfizer has been performing well over the last little while, and recently announced that the European Commission has granted it conditional marketing authorization in the EU for XALKORI® for the treatment of adults with previously treated anaplastic lymphoma kinase-positive advanced non-small cell lung cancer. This is positive news for the company as well as patients. See what our analysts have to say on Pfizer Inc. Follow the Link below
[ http://www.wallstreetactive.com/PFE29October12.pdf ]
While Eli Lilly has been developing a strong pipeline of potential products, its recent quarterly results have been impacted by patent expirations. In its 3rd quarter that company posted an 11% decline in worldwide revenue, in part due to Zyprexa patent expirations. Revenue from its Cymbalta offering improved significantly. However, adjusted earnings per share contracted when compared to the same period last year. Analyst opinion on Eli Lilly & Co. accessible for free at
[ http://www.wallstreetactive.com/LLY29October12.pdf ]
About Wall Street Active:
Walls Street Active offers topmost independent research and investment strategies with the sole purpose of consistently identifying stocks that provide the biggest return on investment for our subscribers. We provide sharp North American stock investing opinion with a truly outstanding success rate. Our goal is for likeminded traders to make a lot of money through our information.
Read our Disclaimer
[ http://www.wallstreetactive.com/disclaimer.html ]
